Nord, Anders
Linner, Rikard
Milesi, Ilaria
Zannin, Emanuela
di Castri, Marco
Bianco, Federico
Dellacá, Raffaele L.
Cunha-Goncalves, Doris
Perez-de-Sa, Valeria
Article History
Received: 3 June 2019
Revised: 21 October 2019
Accepted: 18 November 2019
First Online: 30 November 2019
Competing interests
: Chiesi Farmaceutici SpA, and Politecnico di Milano University, the home institution of I.M., E.Z., and R.L.D., own patents on the atomization of surfactant licensed to Chiesi Farmaceutici. The authors disclose off-label product use of surfactant where it is delivered by a different route of administration, an investigational device for the delivery of aerosol drugs, though indication (Respiratory Distress Syndrome, RDS) and dosage (200 mg kg<sup>−1</sup>) have not been changed. Not related to this study, Politecnico di Milano University, home institution of R.L.D., I.M., and E.Z., received research funding from Chiesi Farmaceutici SpA, ACUTRONIC Medical Systems AG, RESTECH Srl, and Philips AB. The other authors declare no competing interests.
Free to read: This content has been made available to all.